FMP

FMP

Enter

LJPC - La Jolla Pharmaceuti...

Financial Summary of La Jolla Pharmaceutical Company(LJPC), La Jolla Pharmaceutical Company engages in the development and commercialization of therapies that i

photo-url-https://financialmodelingprep.com/image-stock/LJPC.png

La Jolla Pharmaceutical Company

LJPC

NASDAQ

Inactive Equity

La Jolla Pharmaceutical Company engages in the development and commercialization of therapies that improve outcomes in patients suffering from life-threatening diseases. The company offers GIAPREZA, a vasoconstrictor indicated to increase blood pressure in adults with septic or other distributive shock; and XERAVA, a tetracycline class antibacterial indicated for the treatment of complicated intra-abdominal infections in patients 18 years of age and older. It offers GIAPREZA and XERAVA to hospitals and other healthcare organizations in the United States. Its product candidates that are in early stage clinical or preclinical development include TP-6076, an IV formulation of a fully synthetic fluorocycline derivative for the treatment of certain multidrug-resistant gram-negative bacteria; TP-271, an IV and oral formulation of a fully synthetic fluorocycline for the treatment of respiratory disease caused by bacterial biothreat and antibiotic-resistant public health pathogens, as well as bacterial pathogens associated with community-acquired bacterial pneumonia; and TP-2846, an IV formulation of a tetracycline for the treatment of acute myeloid leukemia. The company has license agreement with Everest Medicines Limited to develop and commercialize XERAVA; and PAION AG to commercialize GIAPREZA and XERAVA. La Jolla Pharmaceutical Company was incorporated in 1989 and is based in Waltham, Massachusetts. As of August 22, 2022, La Jolla Pharmaceutical Company operates as a subsidiary of Innoviva, Inc.

6.19 USD

-0.01999998 (-0.323%)

About

ceo

Dr. George Tidmarsh

sector

Healthcare

industry

Biotechnology

exchange

NASDAQ

Description

La Jolla Pharmaceutical Company engages in the development and commercialization of therapies that improve outcomes in patients suffering from life-threatening diseases. The company offers GIAPREZA, a vasoconstrictor indicated to increase blood pressure in adults with septic or other distributive shock; and XERAVA, a tetracycline class antibacterial indicated for the treatment of complicated intra-abdominal infections in patients 18 years of age and older. It offers GIAPREZA and XERAVA to hospitals and other healthcare organizations in the United States. Its product candidates that are in early stage clinical or preclinical development include TP-6076, an IV formulation of a fully synthetic ...

CIK

0000920465

ISIN

US5034596040

CUSIP

503459604

Address

4550 Towne Centre Ct

Phone

18582074264

Country

US

Employee

61

IPO Date

Jun 3, 1994

Summary

CIK

0000920465

Exchange

NASDAQ

Industry

Biotechnology

Sector

Healthcare

CUSIP

503459604

ISIN

US5034596040

Country

US

Price

6.19

Beta

2.41

Volume Avg.

0

Market Cap

0

Shares

-

52-Week

-

DCF

7.59

ROE

-

ROA

-

Operating Margin

-

Debt/Equity

-

P/E

47.62

P/B

-

Website

https://www.lajollapharmaceutical.com

Historical Prices

We are unable to load the chart at this time.

fmp-logo

Financial Statement

We are unable to load the chart at this time.

fmp-logo

Earnings

We are unable to load the chart at this time.

fmp-logo

Upgrades and Downgrades

We are unable to load this data!

fmp-logo

People Also Watch

page loading card

Latest LJPC News

It looks like there's no news available.

fmp-logo
FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedinfacebookinstagram
2017-2024 © Financial Modeling Prep